No. | Assessment | Explanation |
---|---|---|
1. | Blood sample | Blood collection |
- 10 ml of venous blood will be taken by a trained nurse. | ||
- The whole blood will be collected into a plain polyethylene tube until blood clot formation. | ||
- The clots will be separated from the wall of tube using a wooden applicator stick. | ||
- The serum will be separated by centrifugation at 10,000 g at 4 °C for 15 min to eliminate debris and cellular matter. | ||
Blood test | ||
1) Substance P | ||
- The blood serum will be tested using Human Substance P EIA kit (Cusabio Biotech) | ||
2) Cytokines | ||
- The blood serum will be tested individually using Elisa kits to investigate | ||
a) TNF-α | ||
b) IL-1β | ||
c) IL-6 | ||
d) IL-8 | ||
e) IL-10 | ||
c) monocyte chemotactic protein-1 (MCP-1) | ||
d) The soluble form of intercellular adhesion molecule (Sicam-1). | ||
2. | Saliva sample | Saliva collection |
- 3 to 4 ml of unstimulated (resting) whole saliva will be collected 2 min after the patient has rinsed his/hermouth several times with tap water. | ||
- The accumulated saliva in the floor of the mouth will be drawn by a plastic disposable pipette and collected into a plastic polyethylene tube. | ||
- The collected saliva will be centrifuged at 10,000 g at 4 °C for 15 min to eliminate debris and cellular matter. | ||
Blood test | ||
1) Substance P | ||
- The blood serum will be tested using Human Substance P EIA kit (Cusabio Biotech) | ||
2) Cytokines | ||
- The blood serum will be tested individually using Elisa kits to investigate: | ||
a) TNF-α | ||
b) IL-1β | ||
c) IL-6 | ||
d) IL-8 | ||
e) IL-10 | ||
c) monocyte chemotactic protein-1 (MCP-1) | ||
d) The soluble form of intercellular adhesion molecule (sICAM-1). | ||
3. | Visual Analogue Scale (VAS) | - Pain intensity will be measured using VAS by asking the patients to describe their pain level before and after treatment. |
4. | Roland-Morris Disability questionnaire | - Functional disability will be measured using the Roland-Morris Disability questionnaire. |